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Abstract 
 
 
 
 
 
 
 
Finasteride is a 5α-reductase inhibitor widely used in present in the therapeutic approach of 
androgenic alopecia. Adverse effects consist in variable sign and symptoms, the most common being 
represented by mental troubles (reduced feeling of life pleasure or emotions, depression), physical 
impairments (loss of muscle tone and/or mass) and sexual complains (loss of libido and sexual 
potency). An increasing number of studies identify and describe even a post-finasteride syndrome 
(persistent adverse affects three months or more after finasteride cessation) or new adverse effects 
including but not limited at the skin level or oral cavity (marginal periodontium).   
We intend to present in this study several oral adverse effects encountered during finasteride 
administration, represented by mild and moderate signs which generally responded to topical 
procedures without to require the stop of the drug administration. New studies on large samples will 
further document the existing relation between the described oral adverse effects and the implied 
pathophysiological mechanisms. For this moment, we are taking into account as possible 
mechanisms- a direct action of finasteride administration, possible indirect consequences due to 
hormonal interferences, or coexisting factors with finasteride administration that were not detected. 
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Introduction 
Finasteride is a 5α-reductase inhibitor, 
extensively used in present in the therapeutic 
approach of male pattern hair loss. It is approved 
only for men with androgenetic alopecia, being not 
indicated for women or in the case of pediatric 
patients. Finasteride is also used for benign 
prostatic hyperplasia (5mg/ day), being suspected 
that could increase the risk of high-grade prostate 
cancer. In respect to androgenetic alopecia, 
finasteride can be administered in the form of 
tablets, 1mg/ day, or as topical solution applied on 
the scalp once or twice a day (1-3).  
Finasteride is extensively degraded to 
inactive metabolites in liver, which are further 
eliminated through urine and bile. As active 
compound, finasteride prevents conversion of 
testosterone, progesterone and deoxycorticosterone 
to the corresponding metabolites, namely 
dihydrotestosterone (DHT), dihydroprogesterone, 
dihydrodeoxycorticosterone. All these mediators 
act within the brain modulating not only sexual 
receptors but also the action of γ-aminobutyric acid 
on the corresponding GABA receptors. 
Accordingly, the most frequent adverse effects 
induced by finasteride are related to mental 
(depression) and sexual (loss of libido and sexual 
potency) symptoms, which are encountered not 
only during finasteride administration but also 
after treatment cessation (as post-finasteride 
syndrome) (4, 5).    
Recent studies show that finasteride side 
effects can occur at the level of oral cavity too, in 
the form of various signs and symptoms 
(erythema, purpura, gingival hypertrophy) (6, 7). 
The current study is aimed to present oral 
finasteride adverse effects encountered on a 
sample of men taking the drug for androgenic 
alopecia.       
Materials and Methods            
The study group taking finasteride was 
represented by eighty four subjects with 
androgenic alopecia, who received the drug 1 mg 
daily, six month or more. Inclusion criteria used to 
recruit subjects were as follow: men with 
androgenic alopecia, presenting no significant 
(mental, sexual, cutaneous, oral) affections prior 
the treatment, and taking no specific diets or drugs 
for general conditions (obesity, hypertension, etc.). 
According to literature data, finasteride proved to 
be able to induce a lot of adverse effects during 
and after administration. As a consequence, we 
designed and performed the study with several 
specialists to cover a wider field of study, 
including dermatologists, psychiatrists, 
psychologists, urologists, and dentists. Subjects 
were monitored in respect to adverse effects 
encountered not only during therapeutic phase but 
also after treatment cessation, for at least four 
months.  
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Results 
On our sample, the most notable adverse 
effects encountered during therapeutic phase were 
as follow: depression (8,33%), gastrointestinal 
disturbances (5,95%), decreased libido (7,14%) 
and erectile dysfunction (2,38%). At four months 
after finasteride cessation, the “post-finasteride” 
syndrome was represented by depression (4,76%), 
erectile dysfunction (1,19%) and ejaculation 
disorders (2,38%). The subjects included in the 
study received no additional treatments after 
finasteride cessation. 
The gingivo-parodontal lesions were 
encountered during finasteride administration at 
21,42% subjects: 6 with mucosal pallor, 5 with 
erythema, 3 with purpura, 2 with periodontal 
inflammation, and 2 with gingival hypertrophy. 
Excepting the two patients with gingival 
hypertrophy who required discontinuation of 
finasteride to be ameliorated (regressing totally in 
less than three months after finasteride cessation), 
the other oral lesions were treated through specific/ 
local procedures, without to be necessary to stop 
the finasteride administration. 
 
Discussion  
Androgenic alopecia affects nearly 30% of 
men under 30 years, 50% of men over 50 years and 
surprisingly, about 40% of women over 50 years 
(8). It is in part genetically determined, being 
augmented by specific hormonal factor like 
androgens (particularly DHT) that are essential for 
the progression of this condition. Frontal skin 
contains large amounts of 5 α-reductase, the 
androgen-dependent processes from this level 
(DHT binding to the specific receptors) leading to 
androgenic alopecia. The onset of the affection is 
often gradual. Men have thinning hair in the 
temporal areas, the shape of the anterior scalp 
changing. The disease evolves progressively 
towards the frontal area and vertex (9).  
For women it is common a diffuse hair loss, 
and usually in a lesser degree than in men (women 
generally maintaining a frontal hair line). Women 
should not handle finasteride tablets during 
pregnancy due to potential risk to a male fetus. 
When received the drug for idiopathic hirsutism, 
women recorded a hirsutism score that improved 
significantly after 6-9 months after the therapy 
onset (10). 
Pharmacologically, finasteride is a 5 alpha-
reductase inhibitor which acts selectively on type 
II and III isoenzymes. It is a partial inhibition of 
DHT synthesis, due to the fact that finasteride 
doesn’t inhibit the type I of 5 alpha-reductase 
isoenzyme. Consequently, the conversion of 
testosterone to dihydrotestosterone is partially 
inhibited, serum level of DHT decreasing after 
finasteride administration with about 65–70% (11).  
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Finasteride adverse effects described in 
literature differ from study to study. Thus, the 
genitourinary symptoms seems to be not only 
physical but also functional, represented by penile 
and scrotal shrinkage and numbness, decreased 
semen volume and force, erectile dysfunction, 
decreased libido, and decreased or loss of orgasm 
(12, 13).  
Mental and neurological troubles consist in 
memory impairment, decreased comprehension, 
depression, anxiety, suicidal thoughts, insomnia, 
anhedonia and emotional flatness (14, 15).  
Physically, finasteride adverse effects are 
represented by gynecomastia (female-like 
enlargement of the breast), chronic fatigue, muscle 
twitching and atrophy, decreased body 
temperature, increased fat deposition/ elevated 
body mass index, cardiovascular impairments 
(palpitations, hypotension), dermatologic and oral 
manifestations (chronically dry, pruritus, rash, 
urticaria, erythema, purpura, gingival hypertrophy) 
(16, 17).  
It seems that the nature and frequency of the 
above described adverse effects depend not only 
by the study design but also by the sample studied. 
Just an example, it was found that the frequency of 
finasteride side effects would be significantly 
higher when the patients are informed (before 
treatment) about the possible adverse effects, and 
lower/ ignored if the patients would not be advised 
(18).  
A lot of adverse effects related to finasteride 
are encountered not only during Finasteride 
administration but also after treatment cessation, in 
the form of post-Finasteride syndrome. In other 
words, the post-Finasteride syndrome should be 
delineated (as a distinct pathophysiological entity) 
by the adverse effects which are encountered 
during Finasteride administration. Adverse effects 
encountered during finasteride administration 
would be the consequences of a direct finasteride 
action, and indirect consequences of subsequent 
hormonal interferences. After finasteride cessation, 
adverse effects should be assigned only to the 
residual hormonal interferences, represented by 
altered level of certain neuroactive steroids in 
cerebrospinal fluid and plasma. In support of this 
delineation between finasteride and post-
finasteride adverse effects, recent studies show that 
the frequency of finasteride side effects (occurring 
during Finasteride administration) is greater in 
right handed men, while the post-finasteride 
syndrome is encountered with a similar frequency 
in right and left handed men (7, 12, 19).  
A lot of general conditions have (in different 
developmental stages) significant effects at the 
level of oral cavity. The most notable diseases are 
represented by: chronic hepatitis, chronic renal 
diseases, chronic heart failure, venous 
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insufficiency, malignant tumors, nutritional 
diseases and diabetes, immunologic diseases, etc 
(20, 21). 
In addition, there are described more than a 
hundred drugs which may cause side effects to the 
oral mucosa/ marginal periodontium when are 
administered in the curative or symptomatic 
treatment of previously mentioned affections. 
Pharmacological classes including drugs with oral 
side effects are represented by: antidepressants, 
antipsychotics, antihistamines, diuretics, 
antihypertensives, muscarinic antagonists, anti-
inflammatories, bronchodilators, muscle relaxants, 
antimigraine drugs, opioids, benzodiazepines and 
hypnotics, H2 antagonists and proton-pump 
inhibitors, cytotoxic medications, retinoids, anti-
HIV medication and cytokines (alpha interferon)  . 
Clinical manifestations dependent by: drug type, 
dose, the degree of cumulative toxicity, patient 
particularities, etc. These reactions can occur 
immediately, or after days, weeks or months from 
administration onset (22). 
In respect to adverse effects from oral cavity 
we found on our sample (consisting in eighty four 
subjects) that the finasteride adverse effects were 
encountered only during finasteride administration, 
being represented by mucosal pallor (6 patients), 
erythema (5 patients), purpura (3 patients), 
periodontal inflammation (2 patients) and gingival 
hypertrophy (2 patients). Excepting gingival 
hypertrophy (who required discontinuation of 
finasteride administration), all oral lesions were 
treated through specific/ local procedures, without 
to be necessary to stop the drug administration. No 
oral lesions were identified on our sample at three 
months after finasteride cessation (as possible 
signs and/or symptoms of post-finasteride 
syndrome).   
Finasteride and levamisole decrease the 
conversion of testosterone to DHT; in addition, 
these drugs inhibit alkaline phosphatase, an 
enzyme that stimulates the synthesis of DHT (23). 
Conversion of testosterone to DHT is increased in 
gingival inflammation. Yet, DHT is considered to 
be an important stimulator of fibroblast activity 
(24). Starting from these findings, some authors 
suggested that finasteride can be used in the form 
of topical application (in a suitable vehicle) to 
partially block the proliferation of fibroblast 
hyperplasia following phenytoin administration 
(23). 
Testosterone-specific receptors have been 
isolated from periodontal tissue levels (25). The 
number of receptors in the gingival fibroblasts 
tends to increase inflammation or gingival 
hyperplasia (26). At the gingival level, testosterone 
stimulates the matrix synthesis via osteoblasts and 
fibroblasts from periodontal ligament (26- 29), 
stimulates the proliferation and differentiation of 
osteoblasts (30), reduce the production of IL-6 
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during inflammation through inhibition of 
prostaglandin (31- 33), increase the concentration 
of osteoprotegerin (34). 
As a conclusion, finasteride adverse effects 
encountered on our sample at the level of marginal 
periodontium could be the consequences of a direct 
finasteride action, and possible indirect 
consequences of subsequent androgenic 
interferences. 
 
Conclusions 
Male androgenic alopecia is perceived by 
some men as a stressful condition, many affected 
persons resorting usually to specialized assistance 
(from family physician, dermatologists) for 
treatment/ amelioration. The most common 
treatment methods are represented by minoxidil 
and finasteride administration, both drugs being 
efficiently according to clinical studies.  
Even if finasteride seems to be efficiently at 
first glance, recent data show that this drug can 
lead to serious adverse effects like depressive 
symptoms and suicidal thoughts during finasteride 
administration and among former users of 
finasteride with persistent sexual side effects. For 
this reason, it was recommended for Finasteride to 
be carefully administered to patients presenting a 
history or a high risk to developing depression 
(35).      
In respect to our results, finasteride adverse 
effects encountered to oral cavity were mild to 
moderate, and generally responded to topical 
procedures without to require the stop of the drug 
administration. New studies on large samples will 
further document the existing relation between the 
described oral adverse effects and the implied 
pathophysiological mechanisms (direct 
consequence of finasteride administration, indirect 
consequences due to hormonal interferences, or no 
relation to finasteride). Yet, new studies should 
investigate if the subgroup of persons susceptible 
to develop finasteride adverse effects could be 
identified prior to finasteride administration, using 
individual predictive factors (36).       
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